SCHEMBL6191934

SCHEMBL6191934

CCOc1cc(F)ccc1N1CCN(CC2CCc3ccccc3N2C(=O)C2CCCCC2)CC1

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 2/20 0.43
▸ KMT2A Q03164 2/20 0.43
▸ OPRM1 P35372 1/20 0.42
▸ OPRL1 P41146 1/20 0.42
▸ HTR1A P08908 3/20 0.42
▸ ADRA1A P35348 2/20 0.42
▸ ADRA1D P25100 1/20 0.42
▸ ADRA1B P35368 1/20 0.42
▸ RAB9A P51151 1/20 0.40
▸ DRD2 P14416 2/20 0.39
▸ MAPT P10636 1/20 0.39
▸ DRD3 P35462 1/20 0.39
▸ POLB P06746 2/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ ALOX15 P16050 1/20 0.39
▸ MAPK1 P28482 1/20 0.39
▸ DRD4 P21917 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7052092 0.94 HTR1A (0.41) HTR1AADRA1AADRA1DADRA1BDRD2
SCHEMBL6194537 0.92 OPRM1 (0.49) MEN1KMT2AOPRM1OPRL1HTR1A
SCHEMBL6192783 0.92 HTR1A (0.48) MEN1KMT2AHTR1AADRA1AADRA1D
SCHEMBL6192854 0.90 DRD2 (0.45) MEN1KMT2AOPRM1OPRL1HTR1A
SCHEMBL6191391 0.89 ADRA1D (0.45) HTR1AADRA1AADRA1DADRA1BDRD2
SCHEMBL6211824 0.89 DRD4 (0.49) MEN1KMT2AHTR1AADRA1AADRA1D
SCHEMBL6192684 0.87 TSHR (0.47) MEN1KMT2AOPRM1OPRL1HTR1A
SCHEMBL6195130 0.87 POLB (0.44) MEN1KMT2AHTR1AADRA1AADRA1D
SCHEMBL7255376 0.87 HTR1A (0.39) KMT2AOPRM1OPRL1HTR1AADRA1A
SCHEMBL6194300 0.87 HTR1A (0.48) MEN1KMT2AHTR1AADRA1AADRA1D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1432701-B1 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF DISORDERS OF THE URINARY TRACT RECORDATI IRELAND LTD (IE) 2005-12-21 — — EP claimed
EP-1432701-A1 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF DISORDERS OF THE URINARY TRACT RECORDATI S.A. CHEMICAL and PHARMACEUTICAL COMPANY (CH) 2004-06-30 — — EP claimed
US-20030181446-A1 Novel N-acylated heterocycles RECORDATI S.A. 2003-09-25 — — US claimed
WO-2003031436-A1 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF DISORDERS OF THE URINARY TRACT RECORDATI S.A. (CH) 2003-04-17 — — WO claimed
EP-1432701-B1 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF DISORDERS OF THE URINARY TRACT RECORDATI IRELAND LTD (IE) 2005-12-21 — — EP disclosed
EP-1432701-A1 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF DISORDERS OF THE URINARY TRACT RECORDATI S.A. CHEMICAL and PHARMACEUTICAL COMPANY (CH) 2004-06-30 — — EP disclosed
US-20030181446-A1 Novel N-acylated heterocycles RECORDATI S.A. 2003-09-25 — — US disclosed
US-20030162777-A1 Novel N-acylated heterocycles RECORDATI S.A. 2003-08-28 — — US disclosed
WO-2003031436-A1 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF DISORDERS OF THE URINARY TRACT RECORDATI S.A. (CH) 2003-04-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030162777-A1 Novel N-acylated heterocycles HTR1A, HTR1D, HTR1E MEN1 1822/4885KMT2A 2287/4885OPRM1 14/4885
US-20030181446-A1 Novel N-acylated heterocycles HTR1A, HTR1E, HTR2C MEN1 2190/4885KMT2A 3319/4885OPRM1 15/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback